FDA OKs Synthon, Breckenridge ANDA for pioglitazone

02/13/2013 | Healio

Synthon Pharmaceuticals and Breckenridge Pharmaceutical have received federal approval for their abbreviated new drug application for pioglitazone in doses of 15, 30 and 45 milligrams. The drug is indicated for type 2 diabetes, along with diet and exercise.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care